Brian Fries

Jul 30, 2024 | dx.doi.org | Brian Fries |Amanda Hummon

May 29, 2024 | jdsupra.com | Brian Fries

A very large class action settlement has an approaching deadline for class members to file claims.

Sep 13, 2023 | dx.doi.org | Brian Fries |Fernando Tobias |Yijia Wang |Joseph H. Holbrook

Cancerous cells synthesize most of their lipids de novo to keep up with their rapid growth and proliferation. Fatty acid synthase (FAS) is a key enzyme in the lipogenesis pathway that is upregulated in many cancers and has gained popularity as a druggable target of interest for cancer treatment. The first FAS inhibitor discovered, cerulenin, initially showed promise for chemotherapeutic purposes until it was observed that it had adverse side effects in mice.